{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-039837","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.815654+00:00","generated_at":"2026-05-24T16:01:19.342713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MBX Biosciences reports FY2024 net loss of $61.9M; pipeline milestones for 2025","bullets":["Cash and marketable securities $262.1M as of Dec 31, 2024; expected to fund operations into mid-2027.","Phase 2 Avail trial of canvuparatide in hypoparathyroidism fully enrolled (64 patients); topline results expected Q3 2025.","MBX 1416 Phase 1 trial positive; Phase 2 in post-bariatric hypoglycemia to start 2H 2025.","IND submission for MBX 4291 in obesity anticipated in Q2 2025.","Net loss for FY2024 was $61.9M vs $32.6M in FY2023, driven by increased R&D and G&A costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-039837","json":"https://secwatch.observer/filing/0000950170-25-039837.json","markdown":"https://secwatch.observer/filing/0000950170-25-039837.md","text":"https://secwatch.observer/filing/0000950170-25-039837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/0000950170-25-039837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/mbx-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:01:19.342713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}